ReGenesys announces Cell Therapy Manufacturing Award

08-Nov-2012 - Belgium

ReGenesys, subsidiary of Athersys, Inc. announced it recently received the BioProcess International Award for the “Technical Application of the Decade” in Manufacturing for its development of an automated bioreactor system for the production of MultiStem®, Athersys’ proprietary, off-the-shelf stem cell therapy.

The work conducted by ReGenesys scientists, with the support of Terumo BCT, demonstrates that MultiStem cell therapy can be successfully manufactured in an automated bioreactor system. Unlike other cell therapies, the MultiStem product may be manufactured on a large scale, allowing potentially up to a million or more doses to be produced from a single donor. This is enabled by unique biological characteristics that allow for substantial expansion of the cell product in culture, while maintaining potency and product consistency.

“MultiStem has some key advantages relative to other cell therapy approaches, including superior expansion potential, scalability, and distinctive therapeutic properties. This award represents an important demonstration of the manufacturability of MultiStem cells in automated bioreactor systems,” said David Craeye, Sr. Scientist at ReGenesys. “I am excited by the progress made by my team and remain committed to building on our inherent expansion advantages to develop the best-in-class commercial manufacturing platform,” commented Jef Pinxteren, Head R&D.

https://www.bionity.com/en/news/140412/regenesys-announces-cell-therapy-manufacturing-award.html